Get the Stockscreener App
34.21
1.55%
-0.54
After Hours:
34.21
Roivant Sciences Ltd stock is traded at $34.21, with a volume of 6.28M.
It is down -1.55% in the last 24 hours and down -17.53% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$34.75
Open:
$34.275
24h Volume:
6.28M
Relative Volume:
0.91
Market Cap:
$24.71B
Revenue:
$8.26M
Net Income/Loss:
$-397.91M
P/E Ratio:
-67.93
EPS:
-0.5036
Net Cash Flow:
$-758.56M
1W Performance:
-3.63%
1M Performance:
-17.53%
6M Performance:
+21.44%
1Y Performance:
+113.41%
1-Day Range:
$33.32
$34.56
1-Week Range:
$33.32
$36.34
52-Week Range:
$15.90
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.21 | 25.86B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
503.25 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
197.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
739.57 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.63 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.12 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo! Finance Canada
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Roivant Sciences Ltd (ROIV) Stock Price Target & Forecast - TradingKey
Roivant Sciences gains as investors appear to keep rewarding recent clinical and regulatory momentum - Quiver Quantitative
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months - Yahoo Finance
Form 4 Roivant Sciences Ltd. For: 28 September By Investing.com - Investing.com Nigeria
Bernstein Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $41 - Moomoo
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance Singapore
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? - Yahoo Finance
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com Canada
ROIV Looks 361.0% Overvalued on GF Value™ - GuruFocus
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Form 4 Roivant Sciences Ltd. For: 22 September By Investing.com - Investing.com Australia
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Why Roivant Sciences (ROIV) Is Back In The Spotlight - simplywall.st
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12 - marketscreener.com
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Analyzing a 20% Potential Upside Amid Biotech Innovation - DirectorsTalk Interviews
Did Positive PH ILD Trial Data Just Shift Roivant Stock Investment Narrative? - simplywall.st
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data? - Yahoo Finance
Director Melissa Epperly Sells 4,938 Shares of Roivant Sciences Ltd (ROIV) - gurufocus.com
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
ROIV Initiates Coverage by Stifel -- Price Target Announced at $51 - GuruFocus
Roivant Sciences Price Target Announced at $51.00/Share by Stifel - Moomoo
Stifel Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $51 - Moomoo
Stifel initiates Roivant Sciences stock with buy rating, $51 target By Investing.com - Investing.com South Africa
Stifel initiates Roivant Sciences stock with buy rating, $51 target - Investing.com
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Why Roivant Sciences (ROIV) Stock Is Down Today - Quiver Quantitative
Roivant Sciences Director Melissa B. Epperly Forfeits 2,179 Shares at $40.94 Each (NASDAQ: ROIV) - Kalkine Media
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Analysis: High Analyst Confidence with a 12.58% Upside Potential - DirectorsTalk Interviews
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Roivant Sciences Ltd Stock (ROIV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Epperly Melissa B, | Director |
Oct 01 '26 |
Sale |
36.10 |
17,750 |
640,861 |
14,954 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,799,154 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Sale |
36.62 |
200,000 |
7,324,000 |
1,599,154 |
0.97%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):